Relay Therapeutics Inc. (RLAY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)
Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?
Relay Therapeutics (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Why Relay Therapeutics Plummeted by Nearly 14% Today
The biotech firmed up the details of its upcoming secondary share issue. However, the flotation will be dilutive to existing shareholders.
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market
Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor).
Relay Stock Soars on Upbeat Data From Breast Cancer Study
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC.
Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Monday.
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of RLY-2608 alone, in combination with fulvestrant, and combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc‘s PFE selective CDK4 inhibitor).
Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study
Relay Therapeutics said on Monday interim data from an early-stage study of its experimental combination treatment for breast cancer showed it meaningfully extended the time patients lived without their disease worsening.
